NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
18. Januar 2024 00:21 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
07. November 2023 08:50 ET
|
NeuroSigma, Inc.
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation...
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
03. Oktober 2023 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical...
Bioelectronics Market Size 2023 is Bound To Make An Impact Business Trend, Sales Potential, Opportunities with Strategic Growth 2029
21. September 2023 06:15 ET
|
Market Reports World
Pune, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Global Bioelectronics Market [2023-2029] Research Report Analysis and Outlook Insights | Latest Updated Report | 106 Pages Report | The Bioelectronics Market...
NeuroSigma Establishes Singapore Subsidiary
12. Juli 2023 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”) today announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation (“NeuroSigma Singapore”), representing...
NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
01. März 2023 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los...
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
31. Januar 2023 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating...
NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
08. November 2022 10:00 ET
|
NeuroSigma, Inc.
Trials recruiting subjects at UCLA and Seattle Children’s Hospital in the United States, and at King’s College London and the University of Southampton in the United Kingdom Trials sponsored by the...
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
17. Oktober 2022 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...
Gymama Slaughter Appointed Founding Executive Director at ODU’s Center for Bioelectronics
06. Dezember 2021 11:16 ET
|
Old Dominion University
Norfolk, VA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gymama Slaughter has been appointed as the founding executive director of Old Dominion University's Research Center for Bioelectronics. She will lead...